Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of upadacitinib in adult axial spondyloarthritis with remission-withdrawal period
CTR20200194Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of upadacitinib in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by AbbVie Inc.. Started Oct 2020; status: completed.
02
Drugs
upadacitinib
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on CTR20200194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200194.